{
    "nctId": "NCT05034393",
    "briefTitle": "Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil",
    "officialTitle": "Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 308,
    "primaryOutcomeMeasure": "The proportion of type of first-line treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \u226518 years old\n* Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer\n* Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of \u22653\n* HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018\n* Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020\n* Public health system or private health system\n\nExclusion Criteria:\n\n* Male Breast Cancer\n* First-line treatment for mBC received through clinical trial",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}